Hexokinase-2 Expression in <sup>11</sup>C-Methionine-Positive, <sup>18</sup>F-FDG-Negative Multiple Myeloma.
Where this comes from
- Record sourced from PubMed, PMID 30389821.
- Also identified by DOI 10.2967/jnumed.118.217539.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
PET with <sup>18</sup>F-FDG is the standard modality in nuclear medicine for imaging multiple myeloma (MM). However, viable MM as detected by MRI or PET with other metabolic tracers, including <sup>11</sup>C-methionine, may be missed-for example, because of low hexokinase 2 (HK2) expression of tumor cells. The aim of this study was to further investigate potential reasons for PET false negativity. <b>Methods:</b> A cohort of 15 mainly pretreated patients with relapsed or refractory biopsy-proven, serologically active MM who underwent both <sup>18</sup>F-FDG and <sup>11</sup>C-methionine PET/CT was retrospectively analyzed. <b>Results:</b> In 9 of the 15 patients, <sup>18</sup>F-FDG PET was negative in the presence of viable disease. In the remaining 6 patients, both <sup>18</sup>F-FDG and <sup>11</sup>C-methionine PET/CT revealed the same number of MM lesions. At immunohistochemistry, <sup>18</sup>F-FDG-negative myeloma did not exhibit significant differences in HK2 or glucose-6-phosphatase expression from <sup>18</sup>F-FDG-positive disease (<i>P</i> = 0.57 and <i>P</i> = 0.44, respectively). <b>Conclusion:</b> Beyond HK2 expression, <sup>18</sup>F-FDG negativity in (mainly pretreated) MM patients seems to be associated with additional causes not yet known.
Medical subject headings
- Carbon Radioisotopes
- Fluorodeoxyglucose F18
- Gene Expression Regulation, Neoplastic
- Hexokinase
- Methionine
- Multiple Myeloma
- Positron Emission Tomography Computed Tomography